Background: To determine the cardiotoxicity of paclitaxel (T) plus doxorubicin (A) combination therapy in women with advanced breast cancer. To define a dose range of A for use in AT.
Summary
Background: To determine the cardiotoxicity of paclitaxel (T) plus doxorubicin (A) combination therapy in women with advanced breast cancer. To define a dose range of A for use in AT.
Patients and methods: The effect of cumulative A dose on risk of congestive heart failure (CHF) and alterations of myocardial contractility (left ventricular ejection fraction [LVEF] decrease ^20% or to <50%) was estimated from pooled data from 10 trials of AT.
Results: Thirty-one of 657 patients (4.7%) developed CHF at a median of 6.6 months (range 0.3-24.6) after initiation of AT. CHF was stabilized in 29 patients at a median of 17.3 months after diagnosis (range 4.1-31.2 months). The risk of developing CHF was ^ 5% at a total A dose < 380 mg/m 2 . In patients who received a total A dose >440 mg/m 2 , the inci-
Introduction
Anthracyclines have been among the most active drugs for breast cancer for over two decades [1] . Based on early studies reporting the high antitumor activity of paclitaxel (T) in metastatic breast cancer (MBC), and particularly on evidence of response in patients who had failed prior anthracycline therapy, several studies evaluated doxorubicin (A) and T in combination. T was initially administered as a 72-or 24-hour infusion [2] [3] [4] , and later as a 3-hour infusion [5] [6] [7] . The overall response rate was in the range of 43%-94%, and the complete response rate of 18%-41% with the three-hour paclitaxel infusion was particularly promising. This schedule was adopted in later trials due to its tolerability and convenience. Subsequently, an increased risk of cardiotoxicity in patients who received T by 3-hour infusion and the highest cumulative doses of A was noted. In an effort to prevent cardiotoxicity while maintaining the activity of the combination, subsequent trials limited the cumulative A dose to 360-400 mg/m 2 [8] [9] [10] . This empirical decision was based on the observation that the majority of patients who developed congestive heart failure (CHF) did so at cumulative doxorubicin doses > 360 mg/m 2 [8, 9] .
Pharmacological studies of the combination revealed an interaction between A and T that produced increased plasma and tissue concentrations of doxorubicin and its metabolite doxorubicinol [3] [4] [5] [6] [7] [8] [9] [10] [11] . This interaction was accentuated by shorter intervals between A and T administration and with shorter-duration taxane infusion, and could explain the antitumor activity and cardiotoxicity of the combination [3] [4] [5] [6] [7] [8] [9] [10] [11] . Based on this possible pharmacodynamic effect, we evaluated the cardiac safety profile of AT according to two variables based on cumulative A dose and allowing for the interval between the administration of the two drugs and the duration of T infusion.
Patients and methods

Study designs
The analysis evaluated pooled data from 10 studies conducted between March 1993 and November 1997 (Table l) .The 10 studies (Table I) were grouped according to the duration of T infusion and the interval between administration of A and T:
• Group I T infused over 3 hours and a treatment interval of less than one hour.
• Group II T infused over 3 hours and a treatment interval of > 4 hours • Group HIT infused over 24 hours and a treatment interval of 4 hours. In study I (Table I) , the order of A and T administration was alternated in the first two cycles to allow pharmacokinetic analysis. Six of the 10 studies [5] [6] [7] [8] 10 . 12] (studies I. 2, 3. 4. 6, and 8 in Table 1) were open-label, single-ami trials of AT. The remaining four studies were randomized trials, in study 5 [9] , patients were randomized to different treatment intervals between A and T (either 30 minutes [study 5a] or 4 or 24 hours [study 5b]: in study 7 (SWOG 9520). patients received either AT or control therapy (cyclophosphamide plus A); in study 9 (BMS CA139-278). patients received either AT or fluorouracil, doxorubicin. cyclophosphamide (FAC), and in study 10 (ECOG 1193) [14] , patients were randomized to single-agent A, single-agent T, or AT.
In Group I. the dose of A varied from 50 to 60 mg/m 2 and was administered either as an intravenous bolus in < 15 minutes or as a short infusion over 30 minutes. The planned cumulative dose of A for this group ranged from 240 mg/m 2 for patients with locally advanced breast cancer (LABC) in study 6 to 550 mg/m 2 in study 2. Women aged > 18 years who had histologic evidence of MBC were eligible for all studies except study 6. which only allowed patients with LABC or stage 11-111 disease, and study 7. which allowed patients with LABC in addition to patients with MBC. Most studies permitted prior adjuvant chemotherapy if an anthracycline was not included. However, studies 1 and 4 enrolled only patients at first diagnosis of breast cancer who had not received any type of chemotherapy; studies 3 and 8 permitted prior anthracycline use: and study 6 was a neoadjuvanl trial. All studies except study 6 allowed prior use of hormonal or radiation therapy.
All patients in these studies were required to have an ECOG or Southwest Oncology Group (SWOG) performance status of 0-2, adequate hematological. hepatic, and renal function, and left ventricular ejection fraction (LVEF) at or above the lower limit of normal for the participating institution or > 50%. Patients with a history of CHF were excluded from these trials. Written informed consent was required for each patient All studies had been approved by local ethical committees.
Statistical analysis
The cumulative dose of A in mg/m 2 per patient, including anthracycline use prior to study entry, was calculated. For epirubicin, a factor of 0.50 was used to calculate the equivalent dose of A [13] . Cardioloxicity data were analysed according to cumulative A dose (<220. 220-340, 340-380, 380-440, and >440 mg/m 2 ) [13] . These ranges were selected to account for the different dose per cycle given in these trials and cover <3, 4-7 and >8 cycles, respectively, of A 60 mg/m 2 , the dose at which increased cardiotoxicity risk was initially reported No upper limit for the highest dose range was selected due to considerations of meaningful sample size. If a patient had more than one LVEF measurement within an A dose range, the lowest dose was used. CHF was assigned to the lowest cumulative A dose at which the event occurred CHF risk factors, including previous medical history and prior or concomitant radiation therapy, were not taken into consideration because the information was not retrievable for all trials and available for only a minority of patients.
For all evaluations of LVEF change, patients had to have a baseline and at least one post-baseline assessment using the same method of evaluation (MUGA scan or echocardiogram [Echo]). Echo was used for LVEF assessment in studies 1, 3, 4, 6, 8, and 9; MUGA scan was used in all other studies. The life table or actuarial method was used to estimate the probability of CHF or a Common Toxicity Criteria (NCI-CTC) grade 2 alteration of cardiac function (20% decrease relative to baseline) for each cumulative A dose range. For calculation of the incidence of LVEF < 50%, a baseline measurement was not mandatory
Results
Patient andpretreatment characteristics
Studies were selected based on the availability of a complete database in December 1997 and the possibility of source verification. All 10 studies were conducted according to Good Clinical Practice Guidelines. Main patient and study characteristics are summarized in Table 1 . Of note, between June 1993 and September 1995 730 patients with MBC were randomized and treated in the US study in Group III [10] . Pretreatment characteristics (Table 1) were similar between the treatment arms.
Congestive heart failure
A total of 657 patients received AT: 306 in Group I; 108 in Group II; and 243 in Group III. Clinical signs and Stage  IV  IV  IV  IV  IV  II/IIIB  IIIB/IV   IV  IV  IV  IV  IV Table 2 ). The median time to CHF was 6.6 months (range 0.3-24.6 months) after the first dose of AT. Only four patients developed signs of CHF >12 months after starting AT. All patients received adequate intervention for CHF, and CHF improved or was stabilized in 29 patients. Twenty-eight of these patients were followed for >4 months from the time of CHF diagnosis (median 17.3 months; range 4.1-31.2 months). The other patient died of breast cancer two months after completing therapy. CHF was reversible in six patients, as indicated by an improvement in LVEF to near baseline levels or discontinuation of cardiac medication and resolution of symptoms. The two patients who did not respond to cardiac therapy died of AIDS and cardiomyopathy (cumulative A dose 370 mg/m 2 ) and new CNS metastases and profound left ventricular dysfunction (cumulative A dose 358 mg/m 2 ). A formal analysis of cardiac risk factors in all patients could not be performed because the information was not retrievable in all trials. However, age and performance status at study entry had no effect on the development of A-related CHF in patients who received AT, although age had been previously identified as a risk factor in the largest of these trials [14, 15] . In addition, 10 of the 31 patients (29%) with symptomatic CHF had at least one known risk factor for anthracycline-related cardiotoxicity [1] : hypertension in 10; obesity in four; and HIV infection in one. Prior radiation to the left chest wall/heart is a known risk factor but was not evaluated due to lack of consistency in reporting the site of irradiation in patients entered into these trials. However, one patient developed CHF after two doses of AT while receiving concomitant irradiation to a thoracic vertebra. Magnetic resonance imaging showed that altered myocardial contractility was limited to the posterior cardiac wall, which was included in the irradiation field. Prior use of anthracyclines had no effect on the development of CHF in patients in study 3. However, one patient who developed CHF in study 8 had prior anthracycline therapy to a cumulative dose of 266 mg/ m 2 , and received a total A dose of 706 mg/m 2 . CHF incidence was related to cumulative A dose in all three groups, but was < 5% at a cumulative A dose ^ 380 mg/m 2 ( Figure 1 ). The risk of developing CHF increased at 380-440 mg/m 2 of A in Group III, and was >25% in Groups I and II at a cumulative A dose > 440 mg/m 2 ( Figure 1) .
The data from the three randomized studies (7, 9 and 10) allowed the incidence of CHF in patients who received AT and A alone to be compared. In the ECOG trial (study 10) (Table 1) , 245 patients initially received single-agent A, with 132 subsequently crossing over to single-agent T (A-»T; Table 2 ); 242 patients initially received T, with 134 crossing over to A (T -+ A); and 243 patients initially received AT. The risk of developing CHF increased with cumulative A dose in these three treatment arms (Figure 2) , and was 2% (3 of 146), 2% (1 of 65), and 3% (4 of 138) with A->T, T->A, and AT, respectively, with A ^ 380 mg/m 2 . The estimate for the A -*T arm is conservative because three additional patients developed CHF while receiving T after crossover. At cumulative doses of A > 440 mg/m 2 the incidence of CHF in the single-agent arms of study 10 ( Figure 2 ) was comparable (> 25%) to that in patients receiving AT in studies 1, 2, and 3 of Group I (Figure 1) . The increased risk of developing CHF is therefore consistent with the higher cumulative dose of A monotherapy.
Left ventricular function
Myocardial contractility was evaluated in the majority of patients prior to study start and at different time intervals during and after treatment using either MUGA scan or Echo (Table 3) . However, LVEF measurements were available for less than one third of patients in Group 111 and analysis was not performed. The data for Groups I and II were analysed to identify worsening myocardial contractility (LVEF decrease 5= 20% relative to pretreatment levels [NCI-CTC grade 2]) ( Table 4 ) and abnormal contractility (decrease in LVEF to <50%, the level that discriminates between normal and abnormal contractility) ( Table 5 ). In patients who developed CHF, analysis included all LVEF measurements prior to diagnosis.
The data, although incomplete, suggest that NCI-CTC grade 2 toxicity occurs more frequently in patients who later develop symptoms of CHF (Table 4) , with 27% of CHF patients and 4% of non-CHF patients experiencing NCI-CTC grade 2 toxicity. However, 11 CHF patients (73%) never experienced NCI-CTC grade 2 toxicity prior to symptom development. Assessment of the relationship between worsening myocardial contractility and cumulative A dose revealed a progressive increase of the incidence of LVEF decrease > 20% in all assessable patients who received AT, especially at cumulative A doses > 380 mg/m 2 ( Figure 3 ). Table 5 shows the number of patients who had a decrease in LVEF to < 50% with AT therapy, and did or did not develop CHF. Of the 68 patients who had a LVEF measurement of < 50%, 25 (37%) recovered to > 50% following A discontinuation. Of the 38 who continued on T alone following the discontinuation of AT, 12 (32%) showed an improvement to > 50%. No difference between group I and II were observed.
Discussion
The incidence of CHF in the first two studies of bolus A and three-hour T infusion raised concerns regarding the safety of this active combination and prompted a detailed cardiac safety evaluation in subsequent trials. The present analysis of pooled data for AT was performed to determine whether these early reports that AT is a highly cardiotoxic combination are corroborated by additional data, and whether toxic interactions between these drugs could limit the routine use of the combination. In the 10 trials included, 31 of 657 patients (4.7%) developed CHF within a median of 6.6 months after the start of AT. The reported incidence of CHF is high compared lo that in original reports of A cardiotoxicity [15, 16] , but similar to that described for A monotherapy in more recent studies in which careful prospective monitoring of cardiac function was performed [17] . In all studies, the cardiac effects were consistent with anthracycline-associated cardiotoxicity.
The only available data to explain the possible toxic potentiation are studies showing pharmacokinetic interaction between T and A, resulting in increased plasma and tissue exposure to the anthracycline [3, 11] . Therefore, analysis of cardiac tolerability took into account the impact of the interval between the administration of A and Tand the duration of T infusion. An interval of more than one hour between A and T administration limits the effect of the taxane on plasma and tissue concentrations of A and its metabolites because T becomes present after the distribution phase of A. For this reason, patients receiving 3-hour T infusion were analysed in two groups (I and II) defined on the basis of the interval between A and T administration (<30 minutes, Group I vs. ^4 hours, Group II). The demonstration that an increase in plasma anthracycline concentration depends on T concentration indicates that the duration of T infusion could also have a role in the drug-drug interaction [11] . This was the basis for analysing Group III, in which patients received T by 24-hour infusion, separately.
CHF occurred throughout the cumulative A dose range of 120-550 mg/m", but increased in incidence with increasing cumulative dose in all groups. However, up to a cumulative A dose of 380 mg/m 2 , the incidence of CHF was < 5% irrespective of the interval between A and Tadministration (a few minutes to 16 hours) and the duration of T infusion (3 or 24 hours). Furthermore, in the controlled trials included in this analysis, the incidence of CHF was similar in patients treated with AT, A-containing combination therapy, or single-agent A. The conclusion that the addition of T to anthracyclines at cumulative doses of up to 360-380 mg/m 2 does not involve an excessive risk of CHF has recently been confirmed by an EORTC trial that found similar CHF rates in women with MBC treated with AT or A plus cyclophosphamide [18] .
LVEF was analysed only in Groups I and II because data were available for few of the patients in Group III, precluding a meaningful analysis. LVEF followed a pattern of progressive decline during AT treatment, but the extent of any decrease was a poor predictor of clinical events. Although the fact that different methods were used for LVEF determination and inconsistencies in collection of LVEF data in the different studies must be considered, the analysis demonstrated that alteration in myocardial contractility is reversible, even in patients continuing on single-agent T after completion of A.
The cardiotoxicity of AT-dosing regimens other than those mentioned here has been studied. Hudis et al. [19] . No patient experienced symptomatic heart failure and none had a decrease in LVEF to < 50% at any time during treatment. Of the patients who had a decrease in LVEF of > 10%, the majority showed improvement post-treatment. This study indicates that single-agent T has no measurable negative impact on the myocardial damage due to prior exposure to anthracyclines, at least in the range of A total dose administered in the trial.
Another approach to limiting the effects of AT therapy on cardiac contractility may involve the use of a cardioprotective agent. In a trial conducted by Swain et al. [17] , patients with advanced breast cancer were randomized to the cardioprotective agent, dexrazoxane, or to placebo in combination with FAC. Dexrazoxane provided cardioprotection, but there was evidence that the antitumor effect of FAC may have been adversely affected by the use of dexrazoxane because the response rate was lower in patients treated with this drug. However, time to progression and survival were similar in patients who did and did not receive dexrazoxane. Sparano et al. [20] have studied the use of dexrozoxane with AT, and have not observed CHF or a decrease of LVEF of >20% up to a cumulative A dose of 360 mg/m" [20] . However, the same author has recently reported that AT without dexrazoxane in a ECOG single-arm trial produced a significant decrease of LVEF in 21% and CHF in 6% of patients [21] . Based on this observation, the report concluded that AT is associated with excessive cardiac risk that does not justify its use in women with either MBC or primary breast cancer. The decrease of LVEF observed in this ECOG study is similar to that outlined in the present report. However, our analysis indicates that a decrease in LVEF per se is not predictive of clinical toxicity and is reversible even in patients who subsequently receive singleagent T. The incidence of CHF reported by Sparano et al. is also similar to that reported herein, and the data from the EORTC study [19] indicating a similar incidence of cardiac effects, including CHF, with AT and AC corroborates our view that combining T with A does not expose patients to an excessive cardiac risk if the cumulative A dose does not exceed the 360-380 mg/m 2 range.
Finally, T has been studied in combination with epirubicin, a less cardiotoxic anthracycline, in several European studies [22] . The data suggest that this combination is well tolerated without excessive cardiac toxicity. However, this should be considered with caution, because the cumulative epirubicin dose rarely reached the equivalent of 360 mg/m 2 of A, and the risk sharply increased when higher cumulative epirubicin doses were delivered [23] .
In conclusion, a variety of doses and schedules of AT have been evaluated. Evidence suggests that at a cumulative A dose of 340-380 mg/m 2 , 4-6 cycles of AT can be administered to patients with breast cancer with an incidence of cardiotoxicity similar to that of other A-containing combinations. The increase in AT-related cardiotoxicity observed at higher A doses may indicate that the combination is more cardiotoxic, especially when a brief interval between A and a short infusion of T is used. However, it could simply reflect the prospective, serial monitoring of cardiac function that was adopted in these studies, leading to the early recognition of effects that would otherwise have been missed. Only two of the 31 patients who developed CHF in this series died of cardiotoxicity, although CHF due to chronic anthracycline therapy is usually described as a fatal complication in retrospective studies [16] . The present analysis cannot exclude toxic synergy between Tand A, but the results support the empirical limitation on A dose, contribute to the definition of a safe range of cumulative A dose for use as part of AT, and indicate the feasibility of testing AT regimens as adjuvant therapy in controlled trials.
